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Abstract Development of imaging biomarkers is a struc-
tured process in which new biomarkers are discovered,
verified, validated and qualified against biological processes
and clinical end-points. The validation process not only
concerns the determination of the sensitivity and specificity
but also the measurement of reproducibility. Reproducibility
assessments and standardisation of the acquisition and data
analysis methods are crucial when imaging biomarkers are
used in multicentre trials for assessing response to treatment.
Quality control in multicentre trials can be performed with
the use of imaging phantoms. The cost-effectiveness of
imaging biomarkers also needs to be determined. A lot of
imaging biomarkers are being developed, but there are still
unmet needs—for example, in the detection of tumour
invasiveness.
Main Messages
• Using imaging biomarkers to streamline drug discovery
and disease progression is a huge advancement in
healthcare.
• The qualification and technical validation of imaging bio-
markers pose unique challenges in that the accuracy,
methods, standardisations and reproducibility are strictly
monitored.
• The clinical value of new biomarkers is of the highest
priority in terms of patient management, assessing risk
factors and disease prognosis.
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Introduction
There is increasing interest in developing the quantitative
imaging of biomarkers in personalised medicine. Biomarkers
are defined as “characteristics that are objectively measured
and evaluated as indicators of normal biological processes,
pathological processes, or pharmaceutical responses to a ther-
apeutic intervention” [1]. Broadly, biomarkers fall into two
categories: bio-specimen biomarkers, including molecular
biomarkers and genetic biomarkers, and bio-signal bio-
markers or imaging biomarkers. Bio-specimen biomarkers
are obtained by removing a sample from a patient. Examples
of these molecular biomarkers are genes and proteins detected
from fluids or tissue samples. Bio-signal biomarkers remove
no material from the patient, but rather detect and analyse an
electromagnetic, photonic or acoustic signal emitted by the
patient [2]. These imaging biomarkers have the advantage of
being non-invasive, spatially resolved and repeatable [3].
They are of particular interest if they can overcome the limi-
tations of the established histological “gold standards”. In-
deed, invasive reference examinations, such as biopsy, can be
inconclusive, are non-representative of the whole tissue
(which is a tremendous limitation when assessing malignant
tumours, which are known to be heterogeneous) and possess
non-negligible levels of mortality and morbidity.
Genetic biomarkers indicate whether a disease may
occur, but they are usually inefficient to assess the presence
and stage of a disease. Similar to molecular biomarkers,
imaging biomarkers can be used for early detection of dis-
eases, staging and grading, and predicting or assessing the
response to treatment [3]. Accordingly, because of their
relative lower cost compared with imaging, molecular bio-
markers may be more appropriate for disease screening and
early detection than imaging biomarkers. With their high
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sensitivity, molecular biomarkers could also detect subclin-
ical stages of disease before any morphological or functional
change is detectable on imaging. In contrast, imaging bio-
markers are often more useful than molecular biomarkers
for disease staging, and also grading and for assessing
tumour response, because localised information is crucial.
Similar to new drugs, the development of biomarkers has to
pass along a pipeline going from discovery, through verifica-
tion in different laboratories, validation and qualification
before they can be used in clinical routine. Validation includes
the determination of the accuracy and the precision
(reproducibility) of the biomarker and standardisation concerns
both acquisition and analysis. Qualification, defined as a
“graded, fit-for-purpose evidentiary process linking a biomark-
er with biological processes and clinical end-points”, is a
validation process in large cohorts of patients involving multi-
ple centres, similar to phase III clinical trials, to obtain regula-
tory approval as surrogate endpoints [4]. A more extensive
path to biomarker development has been reported [5]. The first
step is the proof of concept, which defines any specific change
relevant to the disease that can be studied using the available
imaging and computational techniques. The relationship
between this change and the presence, grading and response
to treatment of the disease constitutes the proof of mechanism.
The images needed to extract the biomarker must be appro-
priate (in terms of resolution, signal and contrast behaviour).
Preparation of images relates to improving the data before the
analysis (such as segmentation, filtering, interpolation or reg-
istration). The analysis and modelling of the signal by com-
putational numerical adjustment of a mathematical model
allow extracting the needed information (such as structural,
physical, chemical, biological and functional properties).
After this voxel-by-voxel computation, the spatial distribution
of the biomarker can be depicted by parametric images,
defined as derived secondary images which pixels represent
the distribution values of a given parameter. Multivariate
parametric images obtained by statistical modelling of the
relevant parameters allow the reduction of data and a clear
definition of the defined disease target. The abnormal values
should be defined and measured through histogram analysis.
A pilot test on a small sample of subjects, with and without the
disease, has to be performed to validate the process—also
called proof of principle—and to evaluate the influence of
potential variations related to age, sex or any other source of
biases. Finally, proofs of efficacy and effectiveness on larger
and well-defined series of patients will show the ability of a
biomarker to measure the clinical endpoint (Fig. 1).
Accuracy
Before being routinely used in the clinic, imaging bio-
markers must be validated. Determining the accuracy
implies calculating the sensitivity and specificity of the
biomarker when compared with a biological process, such
as tumour necrosis, which can be assessed at histopatholog-
ical examination.
This validation process is challenging because changes
in tissue properties due to diseases that are measured by
imaging, such as the diffusion coefficients at DW-MRI or
the mechanical properties at MR elastography, are only
indirectly linked to structural changes such as necrosis,
cellularity, fibrosis and vascular architecture. Moreover,
the functional properties that are measured may be influ-
enced by other co-existing factors, such as inflammation,
perfusion, permeability and interstitial pressure. For
example, the apparent diffusion coefficient (ADC) is
decreased in chronic liver disease. This ADC decrease
has been shown to be influenced by increased fibrosis,
inflammation and steatosis, as well as by decreased per-
fusion [6–9]. Equating what is measured by imaging and
what is occurring at the cellular level in tissue is a
difficult task because our understanding of the biophys-
ical underpinnings of many imaging biomarkers, such as
diffusion measurements of in vivo systems, remains par-
tial [10, 11].
To help in this understanding, pre-validations studies are
conducted in animal models of the disease of interest, where
histopathological analysis and other invasive reference
examinations can be easily conducted [12]. More basic ex-
vivo research in tissues, phantoms or theoretical models
may also help in the understanding of the relationship
between signal formation and underlying physiopathology
[13]. The transition to the patient has then to be realised, and
the biomarker once again validated using small-cohort then
large-cohort clinical studies.
The ultimate goal for an imaging biomarker is to under-
stand its predictivity so well that it can become a surrogate
for clinical outcome. One primary end-point in therapy
assessment studies is patient survival. No imaging biomark-
er, even the familiar “response evaluation criteria in solid
tumours” (RECIST) [14], universally employed in oncology
drug development, is widely accepted as surrogate for sur-
vival. The RECIST criteria can be used to define time to
progression, but increases in time to progression as a result
of therapy is not necessarily a surrogate of improved overall
survival, as shown by the avastin (bevacizumab) story [14].
In 2011, the FDA withdrew approval for the combined use
of avastin and chemotherapy for the treatment of metastatic
breast cancer because preliminary licensing was predicated
on future demonstration of improvement in survival or
quality of life, both of which were not forthcoming when
clinical trials were completed.
Surrogacy can only be reliably established with a large
number of adequately powered clinical studies using a
variety of interventions, and with the aid of meta-analyses.
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This is a daunting goal, which constitutes the very last step
in biomarker qualification [2].
Reproducibility
Repeatability (measurements at short intervals on the same
subjects using the same equipment in the same centres) and
reproducibility (measurements at short intervals on the same
subjects using different facilities in the same and different
centres) studies must be conducted for image acquisition and
image analysis. These studies have to be performed with the
same observer (intra-observer variability) and with different
observers (inter-observer variability). Repeatability and repro-
ducibility are particularly important to assess if the imaging
biomarkers are to be used in longitudinal studies; for example,
for treatment follow-up, to ensure that the changes in param-
eter are caused by a response to treatment and not by inherent
technical or physiological variation. The reproducibility will
affect the diagnostic usefulness of the biomarker. As an
example, it is known that perfusion parameters are markedly
variable between subjects. Therefore, it has been reported that
post-therapy decrease of Ktrans should at least be in the 30–
50 % range to represent a significant therapy-induced change,
whereas for ADC at DW-MRI a change of 10–20 % would be
sufficient [15]. Reproducibility studies are now very often
included in scientific papers, as advised by the “standards
for reporting of diagnostic accuracy” (STARD) criteria and
should ideally include Bland-Altman plots and results of
coefficients of repeatability [16, 17].
Standardisation
Standardisation relates to the establishment of norms or
requirements about technical aspects. In the development
of imaging biomarkers, two main aspects should be
considered.
Standardisation of image acquisition: similar acquisi-
tion parameters should be used across imaging plat-
forms, when these parameters affect the results of the
biomarker. For example, the calculation of ADC
depends on the number and choice of the gradient “b”
values. A collaborative paper by Padhani et al. [18] lays
the foundation for acquisition standardisation, notably
by recommending that monoexponential assessments of
ADC should use two b values above 100 mm2/s.
Moreover, DW-MRI is very sensitive to motion.
Motion correction schemes are thus advised for DW-
MRI acquisition. However, it is still unclear which
scheme is optimal. As an example for upper abdominal
studies, some consider that free breathing acquisition
produces reliable enough data, even with a better repro-
ducibility than breath-hold, and that a respiratory-
triggered scheme produces less reproducible data, while
others recommend using tracking-only navigator tech-
niques [19–21].
Standardisation of image analysis: volume and region
of interest (ROI) determinations and parameter calcula-
tion (mathematical models) should be standardised. In
tumour perfusion imaging, it has been shown that the
Fig. 1 Steps for the
development of imaging
biomarkers (adapted from [5])
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ROI placements in the vascular input and in the tumour
influence the results and reproducibility of the parame-
ter measurements [22]. To take motion into account,
rigid and non-rigid registration of images at different
time points can be used. In heterogeneous lesions such
as tumours, imaging biomarkers are frequently calculat-
ed as parametric maps with spatial resolution. We need
to define how to handle the histogram that displays the
obtained values. Descriptive statistics such as mean
value, standard deviation, and range can be directly
obtained from the histogram. The main drawback with
this approach is the clear tendency to underestimate the
changes in body tissues and organs, since the values
indicative of disease, or its most relevant manifestations,
are minimised. For this reason, percentiles are used in
some settings to obtain a better relationship with the
most relevant predictive clinical variables. The optimal
type of approach must be defined for each problem
(complete histogram, partial histogram in quartiles, par-
tial histogram in deciles). A further approach involves
the analysis of the heterogeneity in the spatial distribu-
tion of a biomarker provided by its parametric image. To
this end, some distribution asymmetry statistics such as
kurtosis can be used [23–26]. Finally, the choice of the
mathematical model that is used to calculate the quanti-
tative parameters has also a major influence on the
results that are obtained [27, 28]. Standardisation pro-
cedures are currently being developed [18, 29, 30]. It is
important that standardisation be a collaborative effort
of academia and industry. Standardisation of data report-
ing should also be performed. For example, to describe
the liver elasticity in cirrhosis, different units (Young
modulus in kPa, shear modulus in kPa, wave speed in
m/s) and different cut-off values are currently used
[31–33]. Standardisation of these data would improve
the communication between research groups.
Quality control
Adequate phantoms could be used to validate, on a day-to-
day basis, that the biomarker stays robust and to avoid any
drift in the machine, acquisition or processing protocol. The
advantage of using phantoms is that the sequence can be
optimised in detail before being performed in patients (which
is particularly adapted to CT studies to limit the radiation
imposed on the patient), and distribution of the same phan-
tom across imaging platforms allows control of the quality
and standardisation of the procedures. Multicentre quality
control studies have already been conducted using a simple,
ice-water filled, DW-MRI phantom containing tubes of sol-
utions of known diffusion coefficients, which allowed for
comparing machines and centres [34]. For ultrasound and
CT, phantoms ranging from simple gels with inclusions of
different shapes and sizes (for control of tumour size mea-
surement) to complex thoracic models including vasculature
inserts (to test perfusion acquisitions) are available [30, 35].
Mechanically-induced motion of these phantoms can also be
realised [36]. Another possibility is to simulate images based
on computerised phantoms [37]. This computerised phantom
dataset can even incorporate deformation information mim-
icking respiration of patients [23].
Clinical use
When imaging biomarkers are validated for use in drug
development studies or clinical trials, several additional points
should be considered. First, the imaging biomarker should
bring new information on top of existing diagnostic tools or
existing risk factors and have the potential to modify the
patient management [38]. The coronary artery calcium score,
one of the most evaluated cardiovascular imaging biomarkers,
is not only associated with the risk of future cardiovascular
events but it improves the traditional classification of risk by
shifting patients from intermediate to high risk categories [39].
It is likely that a panel of biomarkers will be required to
achieve the high accuracy required at the clinical level.
Second, the imaging biomarker should be completely non-
invasive, for not losing the advantage of safe imaging methods
over invasive reference examinations. Third, the imaging bio-
marker should be cost-effective. If the biomarker is to be added
as part of the clinical routine examination, and not to further
burden the public health systemwith increased costs of care, its
diagnostic advantages have to offset its cost. The imaging
biomarker also should be easy to implement in the clinic,
meaning that the machinery must already exist or be easily
available, that there should not be the need for specific exper-
tise from hospital employees, and that the parameter must be
easy to measure and interpret. Few guidelines currently exist
for imaging biomarker use [40, 41]. Together with other agen-
cies, guidelines, evaluation and implementation may be an
important task for the biomarkers subcommittee of the ESR.
Biomarkers have also a potential for the industry as
pharmacodynamic markers and even surrogate endpoints
for targeted clinical phase I to III studies [42]. Development
of new biomarkers was identified as the highest priority for
scientific effort by the FDA to ease the marketing of newly
developed drugs [43].
Development of new biomarkers
When seeing the difficulties in the qualification and stand-
ardisation of existing imaging biomarkers, is there a need to
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develop additional ones? The answer is yes; for example, in
the field of oncology, where the palette of reasonably well-
understood biomarkers, has major gaps. The hallmarks of
cancer include sustaining proliferative signalling, evading
growth suppressors, resisting cell death, enabling replicative
immortality, inducing angiogenesis, activating invasion and
metastasis, reprogramming of energy metabolism and evad-
ing immune destruction [44]. Regarding angiogenesis, there
are useful biomarkers utilising MRI, CT, ultrasound or PET.
For drugs affecting the deregulated cellular energetics of the
Warburg effect, FDG-PEToffers an obvious assessment. For
cellularity, proliferation and apoptosis, a joint public-private
partnership between the EU and pharmaceutical companies
called “Quantitative Imaging in Cancer: Connecting Cellu-
lar Processes (QuIC-ConCePT)” is currently devoted to the
validation of imaging biomarkers, namely ADC at DW-
MRI, [18F]30-deoxy-30-fluorothymidine PET (FLT–PET)
and isatin-5-sulphonamide PET ([18F]ICMT-11), an apopto-
sis radiotracer with subnanomolar affinity for caspase-3 [12,
45, 46]. However, we currently do not have good markers
for activation of invasion and appearance of metastasis
before these events become macroscopically evident. Thus,
development of new imaging biomarkers is still needed.
The European Society of Radiology and its related Euro-
pean Institute for Biomedical Imaging Research (EIBIR)
should have a relevant role in coordinating future develop-
ments of biomarkers and in the assessment and validation of
imaging biomarkers as surrogate end points.
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